February 2012

Pharma defeats biotech push for rapid approval program

Pharma defeats biotech push for rapid approval program

Fierce Biotech

New CEO = Dendreon Takeover Target?

New CEO = Dendreon Takeover Target?

Motley Fool

Sucampo's Lubiprostone meets primary endpoint in Phase 3 clinical trial for OBD

Sucampo's Lubiprostone meets primary endpoint in Phase 3 clinical trial for OBD

Yahoo/Fly on the Wall

Novo Nordisk Q4 profits jump, outlook raised

Novo Nordisk Q4 profits jump, outlook raised

Yahoo/AP

Merck & Co. swings to Q4 profit on lower charges and 1.6 percent growth in sales

Merck & Co. swings to Q4 profit on lower charges and 1.6 percent growth in sales

Yahoo/AP

AB Soars 46% as Cancer Drug Beats Pfizer’s Sutent: Paris Mover

AB Soars 46% as Cancer Drug Beats Pfizer’s Sutent: Paris Mover

Bloomberg

AstraZeneca to cut 7,300 jobs, post lower profit

AstraZeneca to cut 7,300 jobs, post lower profit

Marketwatch

Pfizer Cites Packaging Flaws in Birth-Control Pill Recall

Pfizer Cites Packaging Flaws in Birth-Control Pill Recall

WSJ Online

J&J’s Zytiga for Prostate Cancer Too Expensive, U.K. Cost Agency Says

J&J’s Zytiga for Prostate Cancer Too Expensive, U.K. Cost Agency Says

Bloomberg

Pfizer: Why It's All In The Pipeline

Pfizer: Why It's All In The Pipeline

Seeking Alpha